Quantcast

IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer

Company to host conference call following ASCO presentation on June 2
to discuss updated clinical data

DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that the
American Society of Clinical Oncology (ASCO)
has published an
abstract on the Company’s clinical study evaluating its lead candidate,
DPX-Survivac, in recurrent advanced ovarian cancer. The abstract was
released online on the ASCO website yesterday in advance of ASCO’s
annual meeting in Chicago, Illinois, taking place May 31 – June 4, 2019.

The final conference poster presentation will include additional data
collected between the abstract submission cutoff date of February 12,
2019, and the presentation itself.

Conference Call and Webcast Information

IMV will host a webcast and conference call to provide an overview of
its ASCO presentation on Sunday, June 2, 2019 at 9:00
a.m. ET. The conference line is (866) 211-3204 (U.S. and Canada)
or (647) 689-6600 (International), and the conference ID# is 8579285. A
live audio webcast and presentation will be available via this
link
and through the ‘Events
and Presentations’
page of IMV’s website.

IMV ASCO 2019 Presentation Detail

Poster Title: “DPX-Survivac
and intermittent low-dose cyclophosphamide (CPA) with or without
epacadostat (E) in the treatment of subjects with advanced recurrent
epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor
infiltration correlate with tumor regression
.”
Abstract
Number
: 5576
Session Title: Gynecologic Cancer
Date
and Time
: June 1, 2019, 1:15 – 4:15 p.m. CT

About DPX-Survivac

DPX-Survivac is the lead candidate in IMV’s new class of immunotherapies
that programs targeted T cells in vivo. It has demonstrated
the potential for industry-leading targeted, persistent, and durable T
cell activation. IMV believes this mechanism of action (MOA) is key to
generating durable solid tumor regressions. DPX-Survivac consists of
survivin-based peptides formulated in IMV’s proprietary DPX drug
delivery platform. DPX-Survivac is designed to work by eliciting a
cytotoxic T cell immune response against cancer cells presenting
survivin peptides on their surface.

Survivin, recognized by the National Cancer Institute (NCI) as a
promising tumor-associated antigen, is broadly over-expressed in most
cancer types, and plays an essential role in antagonizing cell death,
supporting tumor-associated angiogenesis, and promoting resistance to
anti-cancer therapies. IMV has identified over 15 cancer indications in
which the over-expression of survivin can be targeted by DPX-Survivac.

DPX-Survivac has received Fast
Track designation
 from the U.S. Food and Drug Administration (FDA)
as maintenance therapy in advanced ovarian cancer, as well as orphan
drug designation status from the U.S. FDA
 and the European
Medicines Agency (EMA)
 in the ovarian cancer indication. It is
currently being evaluated in multiple Phase 1b/2 clinical trials.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious diseases. IMV
is pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology leverages a
novel mechanism of action that enables the programming of immune cells in
vivo,
 which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T
cell-activating immunotherapy that combines the utility of the platform
with a target: survivin. IMV is currently assessing DPX-Survivac as a
monotherapy in advanced ovarian cancer, as well as a combination therapy
in multiple clinical studies with Merck. Connect at www.imv-inc.com.

IMV Forward-Looking Statements

This press release contains forward-looking information under
applicable securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. In the press
release, such forward-looking statements include, but are not limited
to, statements regarding the FDA potentially granting accelerated
regulatory approval of DPX-Survivac. However, they should not be
regarded as a representation that any of the plans will be achieved.
Actual results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials and the
receipt and timely receipt of all regulatory approvals. IMV Inc. assumes
no responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks and
uncertainties include, but are not limited to, our ability to access
capital, the successful and timely completion of clinical trials, the
receipt of all regulatory approvals and other risks detailed from time
to time in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking statements
and are encouraged to read IMV’s continuous disclosure documents,
including its current annual information form, as well as its audited
annual consolidated financial statements which are available on SEDAR at 
www.sedar.com and
on EDGAR at 
www.sec.gov/edgar.

Contacts

MEDIA
Andrea Cohen, Sam Brown Inc.
O: (917)
209-7163 E: [email protected]

INVESTOR
RELATIONS

Marc Jasmin, IMV Senior Director, Investor
Relations and Communications
O: (902) 492-1819 ext: 1042
M:
(514) 917-9481 E: [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.